Biomx Ltd (PHGE) Stock Price, Quote & News

Company Profile

BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by P...

Industry: Biotechnology

Sector: Healthcare

Phone: 972 7 2394 2377

Website: www.biomx.com

Address:

22 Einstein Street, Floor 4, Ness Ziona, Israel

JohnTrack Jan. 15 at 3:47 AM

$PHGE update just came through https://www.rapidticker.com/news/phge-sec-filing-c1282c

0 · Reply

topstockalerts Jan. 14 at 7:37 PM

$PHGE It just took off with strong follow-through 🚀. Buyers didn’t hesitate. Momentum is fully engaged.

0 · Reply

najch Jan. 14 at 10:55 AM

$PHGE refuses to make new lows - ready to climb higher... first target $7

0 · Reply

kamenrider888 Jan. 6 at 6:49 AM

$PHGE

0 · Reply

kamenrider888 Jan. 6 at 6:49 AM

$PHGE SCAM

0 · Reply

ChartChartist Jan. 5 at 7:58 PM

$PHGE looks good. Get a trade, trade these babies tears for gains whaaaaaaa

0 · Reply

kamenrider888 Jan. 2 at 11:26 PM

$PHGE IS FLATLINED. DO NOT INVEST IN THIS SCAM THAT IS PERPETUATED BY BOILER ROOM BOTS. THIS IS A PUMP AND DUMP STOCK. DO NOT PUT ANY MONEY INTO THIS SCAM. DO NOT WASTE YOUR TIME OR MONEY IN THIS SCAM STOCK.

1 · Reply

najch Jan. 2 at 6:01 PM

$PHGE

0 · Reply

BillionerOfKing Jan. 1 at 8:39 PM

$PHGE Current Stock Price: $1.85

0 · Reply

kamenrider888 Dec. 31 at 4:39 PM

$PHGE NOT WORTH MORE THAN 10CENTS.

0 · Reply

BiomX Announces $3.0 Million Private Placement

Nov 26, 2025, 1:23 PM EST - 7 weeks ago

BiomX Awaits FDA Clearance To Restart Cystic Fibrosis Trial After Nebulizer Device Review

Nov 25, 2025, 4:40 PM EST - 7 weeks ago

BiomX Provides Update on BX004 Phase 2b Trial in Cystic Fibrosis

Nov 12, 2025, 10:31 AM EST - 2 months ago

BiomX Inc. (PHGE) Q3 2025 Earnings Call Transcript

Nov 12, 2025, 7:30 AM EST - 2 months ago

BiomX Reports Third Quarter 2025 Financial Results and Provides Program Updates

Oct 17, 2025, 8:30 AM EDT - 3 months ago

BiomX Provides a Program Update and Announces New FDA Feedback Potentially Expanding BX004 Development Pathways

Aug 19, 2025, 8:19 AM EDT - 5 months ago

BiomX Provides Update on BX004 Phase 2b Trial for the Treatment of Patients with Cystic Fibrosis

Aug 13, 2025, 11:48 AM EDT - 5 months ago

BiomX Inc. (PHGE) Q2 2025 Earnings Call Transcript

Aug 13, 2025, 6:30 AM EDT - 5 months ago

BiomX Reports Second Quarter 2025 Financial Results and Provides Program Updates

Aug 6, 2025, 8:30 AM EDT - 5 months ago

BiomX to Report Second Quarter 2025 Financial Results and Program Updates on August 13, 2025

Jul 14, 2025, 9:00 AM EDT - 6 months ago

BiomX Announces Successful Initiation of Phase 2b Trial with First Patient Dosed in BX004 Program in Patients with Cystic Fibrosis

Jul 8, 2025, 8:30 AM EDT - 6 months ago

BiomX Announces Publication in Nature Communications of Phage Cocktail BX004 Phase 1b/2a Part 1 Data Demonstrating Strong Activity in Cystic Fibrosis

May 19, 2025, 10:02 AM EDT - 8 months ago

BiomX CEO Jonathan Solomon to Present at Biomed Israel 2025 Conference

May 15, 2025, 4:57 PM EDT - 8 months ago

BiomX Inc. (PHGE) Q1 2025 Earnings Conference Call Transcript

May 15, 2025, 6:30 AM EDT - 8 months ago

BiomX Reports First Quarter 2025 Financial Results and Provides Business and Program Updates

May 8, 2025, 7:00 AM EDT - 8 months ago

BiomX to Host First Quarter 2025 Financial Results Conference Call and Webcast on May 15, 2025

Apr 1, 2025, 6:30 AM EDT - 10 months ago

BiomX Announces Compliance with NYSE Guidelines on Audit Opinion Disclosure

Mar 31, 2025, 6:30 AM EDT - 10 months ago

BiomX Announces Positive Topline Results from Phase 2 Trial Evaluating BX211 for the Treatment of Diabetic Foot Osteomyelitis (DFO)

Mar 25, 2025, 6:30 AM EDT - 10 months ago

BiomX Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business and Program Updates

Mar 19, 2025, 12:35 PM EDT - 10 months ago

BiomX to Report Fourth Quarter and Full Year 2024 Financial Results on March 25, 2025

Nov 14, 2024, 10:20 AM EST - 1 year ago

BiomX Inc. (PHGE) Q3 2024 Earnings Call Transcript

Nov 14, 2024, 6:30 AM EST - 1 year ago

BiomX Announces Third Quarter 2024 Financial Results and Provides Business and Program Updates

Nov 12, 2024, 12:20 PM EST - 1 year ago

BiomX to Host Third Quarter 2024 Financial Results Conference Call and Webcast on November 14, 2024

Oct 15, 2024, 7:00 AM EDT - 1 year ago

BiomX Announces a Mandatory Unit Separation

Sep 18, 2024, 8:00 AM EDT - 1 year ago

BiomX to Provide Latest Update on Positive Phase 1b/2a Clinical Trial Data for BX004 at the North American Cystic Fibrosis Conference

Sep 4, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Aug 16, 2024, 10:55 AM EDT - 1 year ago

UPDATE ON UNITS - BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 12:03 PM EDT - 1 year ago

BiomX Inc. (PHGE) Q2 2024 Earnings Call Transcript

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces 1-for-10 Reverse Stock Split

Aug 15, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Second Quarter 2024 Financial Results and Provides Business and Program Updates

Aug 8, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host Second Quarter 2024 Financial Results Conference Call and Webcast on August 15, 2024

Jul 31, 2024, 7:35 AM EDT - 1 year ago

Top 3 Health Care Stocks That May Explode In Q3

DXCM EW

Jul 29, 2024, 7:00 AM EDT - 1 year ago

BiomX Inc. Announces NYSE American Acceptance of Plan to Regain Listing Compliance

Jul 10, 2024, 6:30 AM EDT - 1 year ago

BiomX Inc. Announces Stockholder Approval for Conversion of Outstanding Series X Convertible Preferred Stock to Common Stock

May 30, 2024, 4:50 PM EDT - 1 year ago

BiomX Inc. Receives Notice of Non-Compliance with NYSE American Continued Listing Standards

May 30, 2024, 7:00 AM EDT - 1 year ago

BiomX to Present Phase 1b/2a Clinical Trial Data for BX004 at the 47th European Cystic Fibrosis Conference and at ASM Microbe 2024

May 21, 2024, 10:25 AM EDT - 1 year ago

BiomX (PHGE) Q1 2024 Earnings Call Transcript

May 21, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports First Quarter 2024 Financial Results and Provides Business and Program Updates

May 15, 2024, 7:00 AM EDT - 1 year ago

BiomX to Host First Quarter 2024 Financial Results Conference Call and Webcast on May 21, 2024

Apr 23, 2024, 8:00 AM EDT - 1 year ago

BiomX to Present Data from Phase 1b/2a Study of BX004 for the Treatment of Cystic Fibrosis Patients with Chronic Pulmonary Infections at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID 2024)

Apr 18, 2024, 8:00 AM EDT - 1 year ago

BiomX Announces the Appointment of Susan Blum to its Board of Directors

Apr 3, 2024, 12:26 PM EDT - 1 year ago

BiomX Inc. (PHGE) Q4 2023 Earnings Call Transcript

Apr 3, 2024, 6:30 AM EDT - 1 year ago

BiomX Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update

Mar 27, 2024, 6:30 AM EDT - 1 year ago

BiomX to Host Fourth Quarter and Full Year 2023 Financial Results Conference Call and Webcast on April 3rd, 2024

Mar 18, 2024, 6:30 AM EDT - 1 year ago

BiomX Announces Closing of the Acquisition of Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Mar 6, 2024, 7:30 AM EST - 2 years ago

BiomX Announces Entry into Merger Agreement with Adaptive Phage Therapeutics and Concurrent $50 Million Financing

Jan 4, 2024, 8:00 AM EST - 2 years ago

BiomX Receives Orphan Drug Designation from the U.S. Food and Drug Administration for BX004 for the Treatment of Chronic Pulmonary Infection Caused by Pseudomonas aeruginosa in Patients with Cystic Fibrosis

Nov 30, 2023, 4:15 PM EST - 2 years ago

BiomX to Host Virtual Key Opinion Leader (KOL) Event to Review the Positive Results from Part 2 of Phase 1b/2a Trial of BX004 in Cystic Fibrosis Patients with Chronic Pseudomonas aeruginosa Infections on December 4, 2023

Nov 29, 2023, 6:30 AM EST - 2 years ago

BiomX Announces Positive Topline Results from Part 2 of the Phase 1b/2a Trial Evaluating BX004 for Treatment of Chronic Pulmonary Infections in Patients with Cystic Fibrosis

JohnTrack Jan. 15 at 3:47 AM

$PHGE update just came through https://www.rapidticker.com/news/phge-sec-filing-c1282c

0 · Reply

topstockalerts Jan. 14 at 7:37 PM

$PHGE It just took off with strong follow-through 🚀. Buyers didn’t hesitate. Momentum is fully engaged.

0 · Reply

najch Jan. 14 at 10:55 AM

$PHGE refuses to make new lows - ready to climb higher... first target $7

0 · Reply

kamenrider888 Jan. 6 at 6:49 AM

$PHGE

0 · Reply

kamenrider888 Jan. 6 at 6:49 AM

$PHGE SCAM

0 · Reply

ChartChartist Jan. 5 at 7:58 PM

$PHGE looks good. Get a trade, trade these babies tears for gains whaaaaaaa

0 · Reply

kamenrider888 Jan. 2 at 11:26 PM

1 · Reply

najch Jan. 2 at 6:01 PM

$PHGE

0 · Reply

BillionerOfKing Jan. 1 at 8:39 PM

$PHGE Current Stock Price: $1.85

0 · Reply

kamenrider888 Dec. 31 at 4:39 PM

$PHGE NOT WORTH MORE THAN 10CENTS.

0 · Reply

kamenrider888 Dec. 31 at 12:16 AM

$PHGE

0 · Reply

kamenrider888 Dec. 31 at 12:14 AM

$PHGE this is down over 90% as predicted months ago when I said get out now. Bankruptcy or another reverse stock split into infinity coming...Scam.stock. Scammy management. Do not be fooled by boiler room bots pumping this scam penny stock. DO NOT PUT ANY MONEY ON THIS. IT'S A SCAM.

0 · Reply

StockElementCorporation Dec. 29 at 2:11 PM

Premarket movers 📈 Upside: $DBRG +31% (SoftBank acquires DigitalBridge for $4B EV) $TAOP +14% (HQ relocation, secures $2M smart elevator contracts) $PRAX +9.8% (FDA grants Breakthrough Therapy status for ulixacaltamide) $PHGE +7.5% (announces $3M private placement) $KYIV +3.0% (rallies on potential Ukraine peace agreement) CPNG +2.9% (announces customer compensation plan tied to data breach) Downside: INO -7.9% (no Advisory Committee meeting planned for INO-3107) AXTI -7.7% (prices 7.1M share public offering) HL -4.2% (silver stock weakness after pullback) CDE -4.0% (silver stock weakness after pullback) RARE -3.3% (Phase 3 studies miss primary endpoints)

0 · Reply

DARKP00L Dec. 29 at 1:05 PM

$PHGE 08:05 on Dec. 29 2025 BiomX Commences ~$3M Private Placement Of Series Y Convertible Preferred Stock #tradeideas

0 · Reply

kamenrider888 Dec. 27 at 6:03 PM

$PHGE

0 · Reply

ApolloOptions Dec. 24 at 11:36 AM

$PHGE The longer-term setup revolves around whether management navigates capital constraints while advancing core initiatives. Momentum requires evidence, not projections.

0 · Reply

najch Dec. 22 at 4:37 PM

$PHGE so much hate, will be funny if this pumps now

0 · Reply

kamenrider888 Dec. 21 at 4:48 PM

$PHGE SCAM. Avoid.

0 · Reply

BioTechHealthX Dec. 21 at 4:38 PM

$PHGE Amputations could soon be a thing of the past. BiomX Inc. (NYSE:PHGE) has secured a "clear clinical pathway" from the FDA for its BX011 phage cocktail. Get the exclusive 2026 roadmap for the Phase 2a trial and why this infectious disease play is the hottest ticket on the NYSE American right now. https://biotechhealthx.com/biotech-news/diabetic-foot-breakthrough-the-miracle-virus-from-biomx-inc-phge-you-need-to-watch/

0 · Reply

TWITLIEDETECTOR Dec. 21 at 5:17 AM

$PHGE this company hosed many

0 · Reply

kamenrider888 Dec. 21 at 4:20 AM

$PHGE flatlined already..as predicted

0 · Reply

AranaAcrobat Dec. 19 at 6:13 PM

$PHGE No one is here and I am liking this stock. My bull bot likes it but has sime negative Short Term. Lets play!

0 · Reply

Market Cap	3.46M
Revenue (ttm)	0.00
Net Income (ttm)	-17.73M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	82,900
Avg Vol	105,319
Day's Range	N/A - N/A
Shares Out	1.53M
Stochastic %K	93%
Beta	1.60
Analysts	Sell
Price Target	$26.00